KENNESAW, Ga., March 19, 2012 /PRNewswire/ -- MiMedx Group,
Inc. (OTCBB: MDXG), an integrated developer, manufacturer and
marketer of patent protected regenerative biomaterials and
bioimplants processed from human amniotic membrane, announced today
the signing of a global distribution agreement with Systagenix,
whereby Systagenix will co-market EpiFix®. The MiMedx branded and
proprietary biologic implant specifically processed from amniotic
tissue, EpiFix® offers a wide variety of wound healing and wound
care options.
Based in Gatwick, United
Kingdom, Systagenix will commence its launch of EpiFix®
during March 2012. As part of its
global distribution agreement with MiMedx, Systagenix will
initially conduct the first phase of its global launch of EpiFix®
throughout the United States, with
launches in other countries to follow pending appropriate
regulatory approvals. MiMedx will also continue to sell EpiFix®
through its existing distributor channels.
EpiFix® is another of the MiMedx tissue offerings uniquely
processed through the Company's proprietary Purion(SM) Process to
optimize wound care and ease of use. EpiFix® is an allograft from
amniotic tissue which has been shown to promote the healing of soft
tissues. The Purion(SM) Process retains the amniotic growth factors
inherent in and unique to placental tissue which promotes cellular
ingrowth and enhanced healing.
EpiFix® has unique and differentiating characteristics such as
its 5-year shelf life and stability at room temperature, its ease
of handling and manipulation by physicians, its disinfection
process that protects any compromise of the amniotic membrane
delicate structure and its clinical history and testing results
confirming that EpiFix® retains several growth factors associated
with promoting cell proliferation.
Parker H. "Pete" Petit, Chairman and CEO, said, "We are very
pleased with this opportunity to partner with Systagenix. The
combined efforts of the Systagenix sales and marketing team with
our existing sales, marketing and distribution channels will allow
us to more effectively reach the advanced wound care therapies
segment of the market."
About Systagenix
Established in 2008, following the acquisition of Johnson &
Johnson's advanced wound care
business, Systagenix supplies advanced wound dressings
into over 100 countries worldwide. Information on Systagenix wound
care can be found at www.systagenix.com.
About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of
patent protected regenerative biomaterial products and bioimplants
processed from human amniotic membrane. "Innovations in
Regenerative Biomaterials" is the framework behind our
mission to give physicians products and tissues to help the body
heal itself. Our biomaterial platform technologies include the
device technologies HydroFix® and CollaFix™, and our tissue
technologies, AmnioFix® and EpiFix®. Our tissue technologies,
processed from the human amniotic membrane, utilize our proprietary
Purion(SM) Process that was developed by our wholly-owned
subsidiary, Surgical Biologics, to produce a safe, effective and
minimally manipulated implant for homologous use. Surgical
Biologics is the leading supplier of amniotic tissue, having
supplied over 70,000 implants to date to distributors and OEMs for
application in the Ophthalmic, Orthopedics, Spine, Wound Care and
Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time
or that express management's beliefs, expectations or
hopes. Such statements are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to the
increased usage of EpiFix® within the advanced wound care therapies
market segment as a result of the agreement with Systagenix and the
launch of EpiFix® in countries beyond the U.S. following regulatory
approval. These statements are based on current information and
belief, and are not guarantees of future performance. Among
the risks and uncertainties that could cause actual results to
differ materially from those indicated by such forward-looking
statements include that the increased usage of EpiFix® in the
advanced wound care therapies market segment as a result of the
agreement with Systagenix may not materialize as anticipated, that
the launch of EpiFix® in countries beyond the U.S. may not
materialize or may be delayed due to regulatory approval, and the
risk factors detailed from time to time in the Company's periodic
Securities and Exchange Commission filings, including, without
limitation, its 10-K filing for the fiscal year ended December 31, 2010, and its most recent Form 10-Q.
By making these forward-looking statements, the Company does not
undertake to update them in any manner except as may be required by
the Company's disclosure obligations in filings it makes with the
Securities and Exchange Commission under the federal securities
laws.
SOURCE MiMedx, Inc.